DENTSPLY SIRONA (NASDAQ:XRAY) Announces Quarterly Earnings Results

Key Points

• DENTSPLY SIRONA reported Q results with EPS of $0.27 (missing consensus by $0.01) while revenue beat at $880.0M, and the company updated its FY 2026 guidance to $1.40–$1.50 EPS.
• Shares rose about 1.5% to $11.37 on heavy volume; the stock has a $2.28B market cap, a negative P/E (−3.79) and a 12‑month trading range of $9.85–$17.18.
• Analyst sentiment is mixed (consensus "Hold" with an average target of $13.91), while insiders bought shares and institutions — notably Goldman Sachs — materially increased their holdings.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) posted its quarterly earnings results on Tuesday. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.28 by ($0.01), FiscalAI reports. DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. The company had revenue of $880.00 million during the quarter, compared to the consensus estimate of $841.80 million. DENTSPLY SIRONA updated its FY 2026 guidance to 1.400-1.500 EPS.

DENTSPLY SIRONA Stock Up 1.5%

Shares of XRAY stock traded up $0.17 on Tuesday, hitting $11.37. The stock had a trading volume of 9,456,053 shares, compared to its average volume of 4,456,731. The business has a 50 day moving average of $12.16 and a 200 day moving average of $12.03. The stock has a market cap of $2.28 billion, a price-to-earnings ratio of -3.79, a price-to-earnings-growth ratio of 1.39 and a beta of 0.93. The company has a debt-to-equity ratio of 1.50, a current ratio of 1.51 and a quick ratio of 1.03. DENTSPLY SIRONA has a 12-month low of $9.85 and a 12-month high of $17.18.

Analysts Set New Price Targets

XRAY has been the subject of several research analyst reports. Barrington Research lifted their price target on shares of DENTSPLY SIRONA from $14.00 to $17.00 and gave the company an "outperform" rating in a research note on Monday, March 2nd. Citigroup initiated coverage on shares of DENTSPLY SIRONA in a research note on Wednesday, April 15th. They issued a "sell" rating and a $10.00 price target for the company. UBS Group decreased their price target on shares of DENTSPLY SIRONA from $17.00 to $16.00 and set a "buy" rating for the company in a research note on Tuesday, February 3rd. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of DENTSPLY SIRONA in a research note on Monday, April 20th. Finally, Mizuho raised their price objective on shares of DENTSPLY SIRONA from $14.00 to $16.00 and gave the company a "neutral" rating in a research note on Monday, March 2nd. Three investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $13.91.

Insider Activity

In other news, Director Gregory T. Lucier bought 15,000 shares of the stock in a transaction dated Monday, March 9th. The stock was bought at an average price of $12.45 per share, for a total transaction of $186,750.00. Following the completion of the acquisition, the director directly owned 65,000 shares in the company, valued at approximately $809,250. This trade represents a 30.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director James D. Forbes bought 5,000 shares of the stock in a transaction dated Monday, March 9th. The stock was purchased at an average price of $12.48 per share, with a total value of $62,400.00. Following the acquisition, the director owned 10,000 shares of the company's stock, valued at $124,800. The trade was a 100.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders bought 70,000 shares of company stock valued at $956,437. 0.52% of the stock is currently owned by corporate insiders.

Institutional Trading of DENTSPLY SIRONA

A number of hedge funds have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in DENTSPLY SIRONA during the first quarter worth about $26,000. Goldman Sachs Group Inc. increased its holdings in DENTSPLY SIRONA by 827.3% during the first quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier's stock worth $36,378,000 after buying an additional 2,172,343 shares during the last quarter. Empowered Funds LLC increased its holdings in DENTSPLY SIRONA by 8.8% during the first quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier's stock worth $244,000 after buying an additional 1,320 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in DENTSPLY SIRONA by 7.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 593,021 shares of the medical instruments supplier's stock worth $8,860,000 after buying an additional 41,579 shares during the last quarter. Finally, Focus Partners Wealth increased its holdings in DENTSPLY SIRONA by 59.1% during the first quarter. Focus Partners Wealth now owns 25,181 shares of the medical instruments supplier's stock worth $376,000 after buying an additional 9,355 shares during the last quarter. 95.70% of the stock is currently owned by institutional investors.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc NASDAQ: XRAY is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company's product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.